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Transcription factorElk-1 belongs to the ternary complex factors (TCFs) subfamily of the ETS domain proteins, and plays a critical
role in the expression of immediate-early genes (IEGs) upon mitogen stimulation and activation of the
mitogen-activated protein kinase (MAPK) cascade. The association of TCFs with serum response elements
(SREs) on IEG promoters has been widely studied and a role for Elk-1 in promoting cell cycle entry has been
determined. However, the presence of the ETS domain transcription factor Elk-1 in axons and dendrites of
post-mitotic adult brain neurons has implications for an alternative function for Elk-1 in neurons other than
controlling proliferation. In this study, possible alternative roles for Elk-1 in neurons were investigated, and it
was demonstrated that blocking TCF-mediated transactivation in neuronal cells leads to apoptosis through a
caspase-dependent mechanism. Indeed RNAi-mediated depletion of endogenous Elk-1 results in increased
caspase activity. Conversely, overexpression of either Elk-1 or Elk-VP16 fusion proteins was shown to rescue
PC12 cells from chemically-induced apoptosis, and that higher levels of endogenous Elk-1 correlated with
longer survival of DRGs in culture. It was shown that Elk-1 regulated the Mcl-1 gene expression required for
survival, and that RNAi-mediated degradation of endogenous Elk-1 resulted in elimination of the mcl-1
message. We have further identiﬁed the survival-of-motor neuron-1 (SMN1) gene as a novel target of Elk-1,
and show that the ets motifs in the SMN1 promoter are involved in this regulation.
Crown Copyright © 2011 Published by Elsevier B.V. All rights reserved.1. Introduction
The ternary complex factor (TCF) subfamily of ETS domain
transcription factors, including Elk-1, SAP-1 and SAP-2/ERP/Net, have
been extensively studied with respect to the serum response at the
immediate-early gene (IEG) promoters, most notable that of c-fos
(reviewed in [1]).Withinminutes of serumstimulation, phosphorylation
of the ETS domain factor Elk-1 takes place,which can then form a ternary
complex with the serum response factor (SRF) on the serum response
element (SRE) of the c-fos promoter, thereby activating its transcription
[2,3]. In addition to their role in the immediate growth response, ETS
domain transcription factors have been either implicated or shown to902165780400.
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11 Published by Elsevier B.V. All rigfunction in many developmental processes, from hematopoiesis to
forming functional neural circuits (reviewed in [1,4]).
Interestingly, Elk-1 has been shown to reside in axons and
dendrites of adult rat brain cells, and to be phosphorylated upon
stimulation in these largely post-mitotic neurons [5]. In these neurons
Elk-1 was found to regulate transcription of immediate early genes
such as c-fos and zif268, possibly regulating synaptic plasticity [5].
Furthermore, full-length Elk-1 and an alternatively-translated iso-
form, short Elk-1, have been shown to have opposing roles in PC12
cells. The short Elk-1 isoform (sElk-1) is primarily involved in neurite
extension in NGF-induced differentiation of PC12s [6]. More recently,
Elk-1 was shown to interact with neuronal microtubules [7], and
phosphorylated Elk-1 was shown to translocate to the nucleus upon
stimulation [7,33]. Phosphorylation of Elk-1 on Serine 383/389 was
further shown to regulate dendritic elongation and cytoskeletal
dynamics, as well as SRF and actin levels [33]. SUMOylation mutant
of Elk-1, on the other hand, was shown to both cause faster nuclear
translocation of Elk-1, and consequent neuronal differentiation [22].
Taken together, these ﬁndings suggest that Elk-1 can play additional
roles in neurons beyond a cell cycle response [7,8,22,33]. Indeed, Elk-1
and TCFswere indicated to have an anti-apoptotic role in HEK293 cells
[8], and as such a similar role for Elk-1 could be envisaged in neurons.hts reserved.
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neuronal survival in a range of neuronalmodel cells including both rat
pheochromacytoma (PC12) and human neuroblastoma (SH-SY5Y)
model systems, as well as primary dorsal root ganglia (DRG) cultures.
We present evidence that Elk-1 can enhance survival of these cells,
either by depleting elk-1 mRNA in SH-SY5Y cells through RNA
interference experiments, or by overexpressing a dominant negative
form, ElkEN (engrailed fusion) in PC12 cells. We further show that
exogenous expression of Elk-1 in PC12 cells can protect the cells from
chemically-induced apoptosis. This suggests a potential role of Elk-1
in protecting the cells from apoptosis, or maintaining survival. To that
end, we have investigated two candidate targets for Elk-1, the anti-
apoptotic geneMCL-1, which was previously reported to be regulated
by Elk-1 in other cell types [8,9], and a potential novel target human
SMN1. Our results show that MCL-1 and SMN1 are Elk-1 target genes
in SH-SY5Y neuroblastoma cells and hencemay contribute to the anti-
apoptotic activities of Elk-1 in neuronal cells.
2. Materials and methods
2.1. Materials
Epidermal growth factor (EGF, Sigma E4127) was typically used at
100 nM concentration. Nerve growth factor (2.5 S, Promega) was used
at 50 ng/ml, unless otherwise noted. Cobalt chloride (Sigma) was used
at aﬁnal concentration of 750 μM.1-methyl-4-phenylpyrinidium iodide
(MPP+ iodide, Sigma)wasused at aﬁnal concentration of 1 μM.Caspase
inhibitor Z-VAD-fmk was supplied from Promega and used at a ﬁnal
concentration of 20 μM.
pSRE-Luc (pAS821) contains two copies of the c-fos SRE (nucleo-
tides −357 to −275, containing both an SRF binding site and an
adjacent ets motif) upstream of a minimal tk promoter and the
luciferase gene [8]. pMcl-1-Luc (pAS2156) contains the human Mcl-1
promoter (−3893 to +25) upstream from the ﬁreﬂy luciferase gene
(kindly provided by Steve Edwards). Renilla luciferase was used as an
internal control plasmid. pRSV–Elk-1–VP16 (pAS348) is a Rous sarcoma
virus (RSV) promoter-driven vector encoding full-length wildtype
human Elk-1 fused to residues 410 to 490 of a VP16 C-terminal sequence
[10]. His-FLAG-tagged Elk-1 (pAS278)was reported previously [8]. For in
vivo expression in mammalian cells, pAS1402 (encoding RSV-driven Elk-
(L158P)VP16), pElk-EN, and pElk-(L158P)EN have been described
elsewhere [8,11]. pCDNA3 rIAP-1 construct was kindly obtained from
Dr. M. Holcik. The expression plasmid encoding human wild-type SMN
gene was constructed as follows: Total RNA was isolated from SH-SY5Y
cells with High Pure RNA Isolation Kit (Roche) and 1 μg RNA was
converted into cDNA by High Fidelity cDNA Synthesis Kit (Roche) using
oligo-dT primers. Then the SMN coding regionwas ampliﬁed by using 5′-
AGATC GGA TCC TTT GCT ATG GCG ATG AGC AG-3′ and 5′-AGATC AAG
CTT ATT TAA GGA ATG TGA GCA CCT TCC-3′ primers and the resulting
884 bpproductwas inserted into BamHI/HindIII site of the pCMV-3-tag-6
vector (Stratagene).
The SMN promoter region spanning −553 to +100 with respect to
transcriptional initiator was ampliﬁed from the human genomic DNA as
follows: genomic DNA from SH-SY5Y neuroblastoma cells was isolated
using Wizard SV Genomic DNA Puriﬁcation System (Promega). A 663 bp
PCR fragment of SMN promoter was ampliﬁed by 5′-ACGAGACGGTACC-
CATTCTGACGACAGAGCGAG-3′ and 5′-ACGAGAC AAGCTTTTCTGG-
GAGCGGAACAGTAC primers using Pfu DNA polymerase (Fermentas)
using the following PCRprotocol: 95 °C for 5 min, followed by 30 cycles of
94 °C for 1 min, 60 °C for 1 min and 72 °C for 2 min, and aﬁnal elongation
at 72 °C for 5 min. The resulting promoter DNAwas cloned into KpnI and
HindIII restriction sites of pGL2 plasmid (Promega). Two predicted ets
binding domainswere deleted using theGene-TailorMutagenesis System
(Invitrogen). The SMN promoter, cloned into pGL2 was methylated with
DNAmethylase and thismethylatedDNAwasused as the template for the
subsequent PCR reactions performed with Long PCR Enzyme Mix(Fermentas). 5′-AGGATCTGCCTTCCCCTGCCCCATGTT-3′ and 5′-AAGGCA-
GATCCTTAAACACTAGAAG AT-3′ primers were used for the deletion at
+47 to +50 (deletion 1) and 5′-CAAACAAAAAAAAAAAGGGGAAATA-
TAACACAGTG-3′ and 5′-TTTTTTTTT TTGTTTGTTTGTTTTGAGAC-3′ pri-
mers were used for the deletion at +457 to +459 TT (deletion 2). The
resulting clones carrying the relevant mutations were conﬁrmed by
sequence analysis.
2.2. Tissue culture, cell transfection and reporter gene assays
Rat pheochromacytomaPC12 cellswere routinelymaintained in high-
glucoseDMEMsupplementedwith 10%Horse Serum, 5% Fetal Calf Serum,
1× Penicillin/Streptomycin antibiotics and 1× L-glutamine. SH-SY5Y
human neuroblastoma cells were maintained in low-glucose DMEM
supplemented with 10% Fetal Calf Serum, 1× Penicillin/Streptomycin
antibiotics and 1× L-glutamine. SH-SY5Y cells weremaintained in DMEM
with 10% Fetal Bovine Serum, supplemented with L-glutamine and
antibiotics Penicillin/Streptomycin, at 5% CO2.
Transient transfections with PC12 cells were performed using
500 ng total DNA with Effectene reagent (Qiagen) or more routinely
using 1 μg total DNA with TransFast reagent (Promega) following the
manufacturers' instructions. SH-SY5Y cells were plated into 24 well
plates at 5×104 cells 1 day before transfection and the next day they
were transfected using the TransFast transfection reagent (Promega)
according to the manufacturer's instructions. Usually 400 ng reporter
construct, 200 ng pRL-TK Renilla luciferase plasmid as internal control,
and varying amounts of expression plasmids were transfected into
cells plated as above. After transfection, the cells were maintained in
growth medium for a further 48 h. Then SH-SY5Y cells were scraped
from the plates, spun down, and washed once with ice-cold PBS. For
the luciferase assays, cells were lysed in 100 μl passive lysis buffer
(Promega) and 50 μl of the lysate was placed in 96-well plates, and
luciferase reporter assays were carried out using the dual luciferase
assay system (Promega) according to the manufacturer's instructions.
The assay was monitored and quantiﬁed in Thermo Luminoskan
Ascent and analyzed in MS Excel. Assays were commonly performed
in triplicates, and repeated at least twice.
2.3. Cell survival scoring
The cells were commonly seeded on coverslips in 24-well or 12-well
plates at 5×104 cells/ml. For immunoﬂuorescence-based cell survival
experiments, the coverslipswereﬁxed inmethanol andmounted on glass
slides usingmowiolmountingmediumcontainingHoechst stain (Sigma).
Visualization and scoring of nuclear staining was carried out in pseudo-
confocal ﬂuorescence microscope (Leica). Pictures were generated using
Picture Publisher software (IPLab). For differentiation, neurite extension
beyond almost 2 cell body length was assessed qualitatively and the
number of differentiated cells was counted versus total cells, in at least 3
different ﬁelds per experiment; % differentiation was then reported. For
apoptosis scoring, apoptotic and total nuclei were counted on duplicate
coverslips, for at least three different ﬁelds per coverslip, and % apoptosis
was calculated. For mitotic index estimation, cells in various stages of
mitosiswere countedonduplicate coverslips, at least threedifferentﬁelds
per coverslip.Mitotic index (MI)was calculatedas the average%ofmitotic
cells in the population, and average and standard deviation calculated
using MS Excel software. For surviving cell counts, Trypan Blue exclusion
assaywas used for counting live cells over a period of days and reported in
MS Excel software.
2.4. RNA interference
For RNA interference of elk-1message, psiSTRIKE hMGFP vector was
used as per manufacturer's instructions (Promega), and the constructs
siElk-1 (targeting human Elk-1) and scrRNA (scrambled RNA) have
been described previously [12]. These resulting plasmids were
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TransFast transfection reagent as described by the manufacturer
(Promega). Transfection was repeated 2 consecutive days in a row so
as to ensure complete degradation of the message. Cells were co-
transfected with 1 to 4 μg Elk-1 plasmid, as indicated in text.
Transfection efﬁciency was conﬁrmed by ﬂuorescence microscopy by
observing GFP expression from the RNAi cassette (data not shown).
Seventy-two hours after transfection, cells were collected for RNA
isolation or protein extraction for subsequent analysis.
2.5. Caspase assay
For the measurement of caspase-3 activity, the CaspACE colorimetric
assay systemwas used as permanufacturer's instructions (Promega). SH-
SY5Y neuroblastoma cells were seeded and transfected with scrRNA and
siElk-1 plasmids (2 μg per well) with or without pCMV-SMN (0, 2 or 4 μg
per well). The total DNA amount was equilibratedwith the empty vector,
pCDNA3. Forty-eight hours later, cellswere collected by scraping into cold
PBS and spun down at 1000 rpm. The pellet was washed once with PBS
and collected by centrifugation. Cells were lysed in 100 μl Cell Lysis Buffer
and incubated on ice for 15 min. Theywere frozen and thawed twice and
then centrifuged at maximum speed for 15min at 4 °C. The supernatant
was taken and the protein concentrationwas determined by the Bradford
assay (Sigma). One hundred micrograms μg total protein was incubated
with DEVD-pNA substrate and buffer at 37 °C for 4 h and the activity of
caspase-3 was monitored by measuring absorbances at 405 nm. Mean
intensities were compared using Student's t-test.
2.6. cDNA preparation and Reverse Transcription-Polymerase Chain
Reaction
RNA was isolated from SH-SY5Y cells using the Mini RNeasy isolation
kit (Qiagen), and 1 μg was used for cDNA preparation (MMLTV Reverse
Transcription kit, Fermentas). cDNAs were then normalized for semi-
quantitative RT-PCR analysis using GoTaq polymerase (Promega) and
GAPDH-speciﬁc primers ADS 733 [5′-GCATTGCTGATGATCTTGAGG-3′]
and ADS 734 [5′-TCGGAGTCAACGGATT TG-3′]). Primers used in RT-PCR
reactionswereas follows:mcl-1 forward:5′-GCTCCGGAAACTGGACATTA;
mcl-1 reverse: 5′-CCCAGTTTGTTACGCCATCT; SMN forward: 5′-
GCTGATGCTTTGGGAAGTATGTTA-3′; SMN reverse: 5′-ATTCCAGATCTG-
TCTGATCG-3′. PCR reactions were typically performed at annealing tem-
peratures of 50 °C (GAPDH), 48 °C (MCL-1) and 58 °C (SMN) for 30 cycles.
2.7. Primary DRG cultures and axotomy
Young adult (6–8 weeks) Balb-Cmicewere anaesthetized by an I.P.
injection of ketamin (100 mg/kg, Ketalar, Pﬁzer), killed by cervical
transection and 15–20 DRGs were quickly and aseptically removed
under a stereomicroscope. After trimming all attached nerves in RPMI
1640medium (Sigma) theywere transferred to Neurobasal Amedium
supplemented with 2% B27 (NBA-B27) (Invitrogen) containing 2 mM
Glutamax-I (Invitrogen), 100 units of penicillin, 100 mg streptomycin
and 250 ng amphotericin B per ml (Sigma) and 100 U/ml collagenase
(Sigma). After 50 minof incubation (37 °C, 5% CO2)DRGswerewashed
three times in Hank's buffered salt solution (Sigma) and they were
subjected to further enzymatic digestion with trypsin (1 mg/ml) in
NBA-B27 for 15 min in the incubator. DRGs were then triturated for
about 15 min by gently and repeatedly pipetting through the tips of
narrowing bores (from2 mmdiameter down) and ﬁnally through a 26
gauge injector needle. DNAse (50 mg/ml) (Sigma) was added to the
cell suspension obtained, which was then returned to the incubator and
kept there for another 30 min, this time on a custom made agitator
hortizontally vibrating at 50 Hz. After this, the suspension was spun at
120g for 3 min, the supernatant was discarded and the pellet was
resuspended in NBA-B27 containing 10% fetal calf serum (Sigma) and
700 mg/ml trypsin inhibitor (Sigma) to neutralize the activity of theresidual digestive enzymes. The cell suspension was then carefully
pipettedon topof a three-layerpercol (Sigma)gradient (60%, 35%and10%
from bottom to top) preparedwith NBA-B27 in a plastic tube and spun at
3000g for 20 min in a centrifuge cooled down to 4 °C. Neurons were
collected from 35% layer, washed with NBA-B27 and spun once more at
120g for 3 min; the supernatant was discarded and the pellet was
resuspended inNBA-B27. Thisﬁnal cell suspensionwas seededon35 mm
glass-bottomed Petri dishes (WPI), which had been previously covered
with poly-L-lysine (1.8 mg/cm2, 3 h at RT) and then laminin (40 ng/mm2,
overnight at 37 °C). The dishes were left in the incubator for 2 h to let the
neurons attach to the bottom, after which they were gently washed to
remove unattached cells and remaining debri and ﬁnally ﬁlled with NBA-
B27 and returned to the incubator.
After 48 hof incubation some axons extendedby the culturedneurons
were transected with a laser beam using a laser microdissection
microscope (PALMMicrobeam/Zeiss); thismethod is routinely employed
in the lab soas tomonitorwhathappens to the injuredneuron in real time.
For this study, 2, 5, 10 or 30 min after axotomy, the samples were ﬁxed in
4% paraformaldehyde and processed for Elk-1 or phospho-Elk-1 immu-
noreactivities with indirect immunoﬂuorescence technique (primary
antibodies: rabbit polyclonal anti-Elk-1, rabbit polyclonal anti-phospho-
Elk-1, both fromCell Signalling; secondary antibody: Alexa ﬂuor 488 goat
anti-rabbit IgG, Invitrogen). In a parallel set of experiments, preparations
were incubated with propidium iodide (PI) for 24 h following axotomy,
after which they were washed thoroughly with PBS, ﬁxed and processed
for Elk-1 immunoreactivity to compare the Elk-1 contents of dead and live
neurons. Fluorescence imaging in both sets of experiments were
performed using a laser scanning confocal microscope (Zeiss LSM 510
Meta) and staining intensities of neuronal somata were measured with
LSM 3.0 software. Mean intensities were compared using Student's t-test.
2.8. Chromatin immunoprecipitation
Cells were plated in 15 cm dishes at 2×106 cells/ml. On the next
day, they were transfected with 5 μg ElkVP16-Flag and 5 μg SMN-Luc
promoter constructs (wildtype or deletions) using TransFast trans-
fection reagent as described above. After 2 days, DNA and proteins
were crosslinked in 1% formaldehyde for 10 min and then quenched
with 0.1 M glycine solution. Cells were scraped and suspended in
hypotonic nuclei isolation buffer and incubated for 10 min on ice for
swelling. 1%NP-40 was added to swollen cells, and vortexed to
separate nuclei from cytoplasm. Nuclei were pelleted at 5000 rpm for
3 min in a cold centrifuge. The pelleted nuclei were digested with
micrococcal nuclease (New England Biolabs) at 37 °C for 10 min and
the reaction was stopped with 10 mM EDTA. After centrifugation at
15,000 rpm, the supernatant containing digested chromatin was
collected and diluted to 1 ml with the dilution buffer (see Millipore
EZ-ChIP kit for recipe). The chromatin was pre-cleared with 50 μl
protein-G agarose beads for 1 h. Immunoprecipitations were carried
out overnight at 4 °C with mouse monoclonal anti-FLAG (Sigma) and
mouse monoclonal anti-IgG (Upstate) antibodies. Antibody–protein–
DNA complexes were precipitated with 50 μl protein G-agarose beads.
Beads were washed with low-salt buffer, high-salt buffer, LiCl buffer
and TE buffers (see Millipore EZ-ChIP kit for recipes) consecutively.
After elution of proteins from beads, samples were incubated with
NaCl at 65 °C for overnight to reverse the cross-link. Then after RNaseA
and proteinase K treatments as per manufacturer's instructions,
immunoprecipitatedDNAwaspuriﬁedby a spin column in 20 μlwater.
PCR was performed with the primers (ets2 forward) 5′-CGA CAG
AGC GAG ATT CCG TTT C-3′ and (ets2 reverse) 5′-CCT TGG AAA AGT
AAATGTAAGCTCCTA-3′ at 55 °C annealing temperature for 35 cycles ,
orwith primers (ets1 forward) 5′-AAAAATAGCTGAGCTTGGTGGCG-
3′ and (ets1 reverse) 5′ACCGCT TGT AGT AAC TTC TCA CGC-3′ at 58 °C
annealing temperature for 35 cycles, using Taq polymerase (Fermen-
tas). PCR products (176 bp for ets2 region, and 293 bp for ets1 region)
were run in 1.5% agarose gels and visualized by ethidium bromide
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QuantityOne software, by measuring band intensities and subtracting
the IgG background bands, then calculating Flag IP⁄input values. The
average data are reported where input is assumed to be 1 unit.
3. Results
3.1. The dominant repressive Elk-EN fusion interferes with PC12 survival
To investigate the function of Elk-1 in neurons, we have used a set
of different model systems, including the PC12 pheochromocytoma
cell line. PC12 cells are tumors of the chromafﬁn cells of the adrenal
medulla, and having originally derived from the neural crest during
development, they can be used as model systems for neuronal
differentiation. When treated with epidermal growth factor (EGF),
these cells proliferate without differentiating; on the other hand, if
treated with nerve growth factor (NGF), they undergo neuronal
differentiation as monitored by the expression of neuronal markers as
well as electrical activity (reviewed in [13]).
Initially the effect of the dominant repressive Elk-Engrailed (Elk-EN)
fusion protein in PC12 cells was tested. This fusion contains full-length
Elk-1 and the potent transcriptional repression domain from the
engrailed transcription factor [8]. Since Elk-EN can bind to the ets
motifs on DNA equally well as Elk-1 and other TCFs, it can displace
endogenous Elk-1 and hence repress all endogenous targets of the TCF
subfamily ([8], Fig. 1A). In PC12 cells, Elk-EN can repress an Elk-VP16-
activated SRE-Luc reporter construct in a dose-dependent manner
(Fig. 1B). Having shown the functionality of Elk-EN in PC12 cells, we
have next monitored the differentiation of NGF-stimulated cells in the
presence of increasing amounts of Elk-EN (Fig. 1C).While EGF gave low
level of differentiation response, treatment of NGF led to much higher
levels of neuronal differentiation in PC12 cells as determined by
morphological changes (see Section 2.3). Transfection of PC12 cells
with increasing amounts of Elk-EN could to a certain extent repress
neuronal differentiation in a dose-dependent manner (Fig. 1C). In
parallel sets of experiments we could show that while EN expression
plasmid in the presence of NGF stimulation did not reduce the ratio of
differentiating cells, increasing amounts of exogenous ElkEN expression
did result in some decrease in the overall differentiation scores in the
presence of NGF (Fig. 1D). Differentiation in these assays was scored as
neurite extensions more than twice the length of cell soma (see arrows
in Fig. 1E), andpresence of exogenousElkENreduced this differentiation
and atmost short neurite extensionswere observed (those not counted
as differentiated cells, see arrowheads in Fig. 1E). Expression of Elk(LP)
EN, the SRF-interaction mutant that will be explained later in the text,
however, did not cause as much reduction in differentiation (Fig. 1E).
This result could be interpreted in twoways: either Elk-EN could be
inhibiting differentiation itself (i.e., Elk-1 could be actively promoting
differentiation) (as argued in [6]; also see Section 4), or Elk-EN simply
reduces the survival of differentiating cells through promoting cell
death (i.e., Elk-1 facilitates survival). In order to address this critical
question, we initially carried out a very straightforward survival assay,
where the number of surviving cells was monitored over a period of
4 days in response to increased levels of transfected Elk-EN plasmid
(see Section 2.3). Our results showed that the higher the exogenous
Elk-EN, the lower the number of surviving cells (Fig. 1D).
3.2. Elk-EN expression causes an increased amount of caspase-dependent
apoptosis in PC12 cells
In order to distinguish whether the decreased survival was due to
apoptotic cell death or some other means of elimination of the cells,
we have stained the PC12 nuclei using Hoechst dye. When PC12 cells
were transfected with control plasmid, nuclei were healthy, mostly in
interphase, and a few in mitosis (Fig. 2A, long arrow). Transfection of
Elk-EN plasmid to PC12 cells led to apoptotic blebbing of many nuclei(Fig. 2A, short arrows). When Elk-EN was co-transfected with the
constitutively active Elk-VP16 construct, apoptotic blebbing was lost.
On the contrary, when an SRF-interaction mutant (Elk-L158P, where
the Leucine in the SRF-interaction domain, B-box, is mutated [11])
fused to Engrailed repression domain (Elk-(LP)-EN) was used,
apoptotic blebbing was almost negligible in PC12 nuclei (Fig. 2A).
When this set of data was scored for apoptotic levels and mitotic
index (MI), they were seen to be inversely correlated (Fig. 2B).
In order to convincingly show that this apoptotic blebbing was
indeed due to caspase-mediated apoptosis, a similar set of experi-
ments was performed in rat PC12 cells, using two different means of
inhibiting apoptosis: we have either transfected the cells with an
empty control plasmid or the Elk-EN expression plasmid as in Fig. 2A
and B, but in addition we have either co-transfected the cells with
both Elk-EN and rat inhibitor of apoptosis protein (rIAP-1) plasmid, or
treated the cells with a chemical caspase inhibitor Z-VAD-fmk prior to
transfection (Fig. 2C). Elk-EN was unable to cause apoptosis in the
presence of either rIAP-1 or Z-VAD-fmk (Fig. 2C), indicating that the
death response was indeed caspase-dependent.
3.3. ExogenousElk-1 canprotect neurons fromchemically-inducedapoptosis,
while degradation of endogenous Elk-1 promotes caspase activation
Since the experiments above were conducted using a dominant
repressive form of Elk-1, one could argue that the apoptotic response
we have observed was due to the artiﬁcial overexpression of this
construct, and thus not correlated to the real function of endogenous
Elk-1. To address these concerns, we have carried out two sets of
experiments.
Firstly, we wanted to address whether overexpression of either
Elk-1 or a constitutively active form, Elk-VP16, could rescue PC12 cells
from apoptotic cell death. To that end, we have used a known
chemical inducer of apoptosis, cobalt chloride [14,15]. When cells
were transfected with an empty control plasmid, treatment with
cobalt chloride resulted in a signiﬁcant decrease in the surviving cell
population (Fig. 3A). However, when cells were priorly transfected
with expression plasmids encoding either Elk-1 or Elk-VP16, the
decrease in cell number was nearly 3-fold lower (Fig. 3A).
Using a different apoptotic inducer, MPP, in SH-SY5Y neuroblastoma
cells, we have shown that this pro-survival function of Elk-1 could be, at
least to some extent, SRF-dependent. In the absence of MPP, the ectopic
expression of Elk-EN decreased the number of surviving cells, while the
SRF interaction mutant Elk(LP)-EN showed less decrease. Expression of
Elk-VP16, and to a lesser extent Elk(LP)VP16, showed a slight increase, if
any, in the number of surviving cells in culture (Fig. 3B, dark bars), while
Elk-1 expression did not signiﬁcantly alter the number of surviving cells.
On the other hand, the treatment of control cells with MPP reduced cell
survival by nearly half, which was only partly rescued by Elk-1, but
signiﬁcantly enhanced by Elk-VP16 (Fig. 3B, light bars). Elk(LP)-VP16
was also able to rescue the cells to a certain extent. Elk-EN reduced cell
survival even further in the presenceofMPP, but survival inMPP-treated
cellswas not signiﬁcantly changed in thepresenceof Elk(LP)-EN (Fig. 3B,
light bars).
3.4. Higher levels of endogenous Elk-1 correlates with higher survival
rates in primary DRG neurons, with or without axotomy
In order to understand how Elk-1 might affect cellular function in
healthy versus injured neurons, we studied Elk-1 in an in vitro
neuronal injurymodel, axotomyof primary neuronal cells. To that end,
we have employed primary DRG cultures, and analyzed the survival of
cells in culture, with or without axotomy, in relation to endogenous
Elk-1 levels and its phosphorylation (see Section 2.7). It should be
noted that 24 h following axotomy, approximately 50% of axotomized
neurons die; this rate is only 5% under control conditions (data not
presented).
Fig. 1. A dominant repressive form of Elk-1, namely ElkEN, can repress transcription from the ets motif and result in decreased differentiation and cell survival in PC12 cells. (A) A
schematic diagram showing that ElkEN can bind to ets motifs, interact with its partner protein SRF and repress transcription of TCF-responsive genes. (B) Transfection of a
constitutively active fusion, ElkVP16, into PC12 cells in increasing amounts (50 and 100 ng) leads to increased luciferase activity from an SRE-Luc reporter plasmid. Co-transfection of
increasing amounts of ElkEN represses ElkVP16-induced transcription up to 10-fold in PC12 cells. (C) PC12 cells were either stimulated by EGF (100 μM) or NGF (50 ng/ml) for 3 days
and scored for differentiation. Cells were co-transfected with GFP along with either empty control plasmid (pCDNA3) or Elk-EN expression plasmid in increasing amounts (50, 100,
250 ng/well) 1 day prior to growth factor treatment. The differentiation scores are quantiﬁed in Excel and shown in graphs; (D) In a parallel set of experiments, cells were co-
transfected with GFP along with either empty control plasmid (pCDNA3, 250 ng), EN or Elk-EN expression plasmid in increasing amounts (100 and 250 ng per well) 1 day prior to
growth factor treatment and treated with NGF for 4 days. The differentiation scores are quantiﬁed in Excel and shown in graphs (*pb0.16; **pb0.2; both compared to NGF control);
(E) a parallel set of transfections for NGF, NGF+ElkEN or NGF+Elk(LP)EN were studied under epiﬂuorescence microscope (representative images are shown; arrows indicate
representative images quantiﬁed as differentiation; arrowheads indicate neurite extensions that are smaller than the accepted threshold and thus not quantiﬁed as differentiation).
(F) Average number of surviving PC12 cells upon increasing amounts of Elk-EN transfection. Live cells were counted in a minimum of three ﬁelds per well, in at least two wells per
assay. Data shown are from day 3 after transfection and represent cell survival for days 1–4.
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surviving were analyzed for their Elk-1 immunoﬂuorescence inten-
sities (24 h after axotomy), it was seen that the “dead” cells exhibitedessentially similar levels of Elk-1, however those that survived, or
“live” cells, exhibited higher levels of Elk-1 irrespective of axotomy
(Fig. 4A). The axotomized “live” cells (mimicking survival after
Fig. 2. Elk-EN-dependent cell death is via caspase-dependent apoptosis. (A) PC12 cells were either transfected with control vector pCDNA3 or with the dominant repressive form,
Elk-EN, and nuclei were stained with Hoechst dye. Representative images of mitotic cells (long arrows) and apoptotic nuclei (short arrows) are indicated. (B) Quantiﬁcation of
percent apoptosis and mitotic index (MI) in the experiments presented in (A). (C) PC12 cells were either transfected with a control plasmid, ElkEN expression plasmid on its own, or
in the presence of either a rat IAP-1 (rIAP1) expression plasmid or the caspase inhibitor Z-VAD-fmk. Quantiﬁcation of percent apoptosis and mitotic index (MI) was scored.
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non-axotomized “live” cells (mimicking survival of healthy, un-
damaged neurons), which could be due to the relatively shortened
length of the axons, and loss of microtubule-associated Elk-1 [7].
These results appear to be speciﬁc for Elk-1, since immunoreactivity of
another ETS domain transcription factor, PEA3, does not show any
signiﬁcant change in ﬂuorescence intensities (data not shown).
We then investigated the kinetics of Elk-1 phosphorylation following
axotomy in these primaryDRGs over a period of 30min after axotomy. In
order to provide statistically signiﬁcant semi-quantiﬁcation of immuno-
ﬂuorescence intensities, we have measured Elk-1 and phospho-Ser383-
Elk-1 immunoﬂuorescences in non-axotomized cells within the same
culture, and normalized those from axotomized neurons accordingly.
When datawere analyzed, it was observed that the amount of total Elk-1
peaked at around 5 min following axotomy, after which it reached a
plateau, while the amount of phospho-Ser-383-Elk-1 started to increase
10 min after axotomy up until 30 min (Fig. 4B). This relatively fast
accumulation of Elk-1 could be due to potential local translation events,
since bioinformatics analysis indicates presence of putative dendritic and
axonal localizationmotifs in the untranslated regions (UTRs) of the elk-1
mRNA (see Section 4). Both axotomized and uninjured neurons had
signiﬁcantly higher Elk-1 immunoreactivity if they had survived,
compared to the ones that had died during 24 h of incubation (Fig. 4A).
This change in immunoﬂuorescence intensities appears to be signiﬁcant
and speciﬁc to Elk-1, since immunoﬂuorescence intensities for another
ETS domain factor, PEA3, does not change before andafter axotomy (data
not shown).The serum-induced nuclear translocation of phospho-
Ser383-Elk-1 was previously shown [7]. Our hypothesis is that in this
neuronal injurymodel, axotomy could serve as another signal generatingan increase in phospho-Elk-1, leading to enhanced survival of the injured
neuron.
3.5. MCL-1 is a target of Elk-1 in neuronal survival
If the function of phospho-Elk-1 is to ensure survival of the neuron
involved, then it is likely that this transcription factor would induce
expression of survival-related genes. There are a number of survival-
related promoter sequences with putative ets motifs to which Elk-1
can bind, as well as some known Elk-1 targets in other cell systems.
Mcl-1, a member of the Bcl-2 family, was previously shown to be
an anti-apoptotic target of Elk-1 in the HEK293 cell line as well as in
hematopoietic cells [8,9]. We therefore wanted to address whether
Mcl-1 is regulated by Elk-1 in a neuronal context. To that end, we
initially performed luciferase reporter assays using MCL-1-Luc
reporters with a constitutively active Elk-VP16 fusion protein, and
observed a signiﬁcant increase in luciferase activity (Fig. 5A). No
reporter activity was observed when an SRF interaction-deﬁcient Elk
(LP)-VP16 construct was used (Fig. 5A), and repression was observed
by Elk-EN in PC12 cells (data not shown). However, to bemore certain
about the validity of this regulatory correlation, we performed RNAi-
mediated depletion of endogenous Elk-1 in SH-SY5Y cells. These cells
were selected because of their higher transfection efﬁciency when
compared to PC12 cells, so as to make sure that we have a substantial
knock-down. When cells were transfected with a scrambled RNA
(scrRNA) control plasmid, where Elk-1 protein was still present [12],
human MCL-1 mRNA levels were unaffected in RT-PCR experiments.
However, when increasing amounts of a plasmid expressing siRNA
duplex directed against Elk-1 (siElk-1) were transfected into SH-SY5Y
Fig. 3. Elk-1 can protect neuronal cell lines from apoptosis. (A) PC12 cells were transfected
either with control plasmid, Elk-1 or Elk-VP16, and treated with cobalt chloride, a known
apoptosis-inducing agent. Live cells were scored and results are representative of surviving
cells at the end of day 2. (B) SH-SY5Y neuroblastoma cells were transfected either with
plasmid control plasmid, Elk-1, ElkEN, Elk(LP)EN, ElkVP16 or Elk(LP)VP16 expression
plasmids, and treated with MPP, a known apoptosis-inducing agent. Live cells were scored
and results are representativeof survivingcells at theendof48 h in thepresenceorabsenceof
1 μMMPP. (*pb0.1 vs relevant control in−MPP and +MPP conditions).
Fig. 4. High levels of Elk-1 expression are correlatedwith higher rates of survival in primary DRG c
dead neurons. The bold arrow points to an axotomized dead neuron while thin arrows indicate th
withingroups;Elk-1 ingreen, PI in red,merged image labeledPI+Elk-1). (B)Elk-1andPhospho-El
three typical axotomizedneurons5 and30min after axotomy. Changes in theﬂuorescence intensit
and #pb0.05 vs control for Elk-1p).
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indicating that presence of endogenous Elk-1 is important for
maintenance of MCL-1 in these cells.3.6. Survival motor neuron 1 (SMN1) as a potential novel target of Elk-1
The SMN proteins are components of a large complex that regulate
the biogenesis of components of the RNA splicing machinery, and
reduced levels of SMN1 correlates with a neurological disorder known
as spinal muscular atrophy, SMA, where motor neurons selectively
degenerate [16]. The homozygous absence of which leads to
spinomuscular atrophy (SMA), a neurodegenerative disorder with
progressive loss of motor neurons. SMN1 and SMN2 are two copies of
the same gene on different chromosomal locations (telomeric and
centromeric regions of chromosome 5q, respectively; [17]). SMN2
codes for a shorter copy due to exon skipping, and cannot compensate
for the absence of SMN1 in SMA patients. The promoter sequences for
both SMN copies appear to be identical [17], and contain two ets
motifs (see also [5], and Section 4). We therefore investigated
whether the SMN promoters are genuine targets for regulation by
Elk-1. When endogenous Elk-1 levels were knocked down by RNAi in
SH-SY5Y cells, we have observed a decrease in the levels of not only
the SMN1 message, but also of SMN2 (Fig. 6A). This was further
conﬁrmed at the protein level (Fig. 6B). To analyze whether this is a
direct effect of transcriptional regulation by Elk-1, we have cloned the
human SMN promoter upstream from a luciferase reporter gene.
When SH-SY5Y cells are transfectedwith the constitutively active Elk-
VP16 expression plasmid, there was a nearly two-fold increase in the
promoter activity, which was reduced when cells were transfectedultures. (A) Elk-1 immunoﬂuorescence intensities in live and dead cells. PI stains the nuclei of
e cells that survived the axotomy at the time of analysis. (see Section 2; *pb0.05 live vs dead
k-1 (Elk-1p) levels in culturedDRGneurons followingaxotomy.The images in thepanels show
yrelative to control preparationswere expressedaspercentages. (*pb0.05vs control for Elk-1,
Fig. 5. Elk-1 can regulateMCL-1, a pro-survival gene, inSH-SY5Yneuroblastomacells. (A)Elk-
VP16,butnotElk(LP)-VP16, canactivateanmcl1-Luc reporter construct in SH-SY5Ycells. Cells
were co-transfected with mcl1-Luc reporter construct along with either pCDNA3 empty
control plasmid, or expression plasmids encoding either Elk-VP16 or Elk(LP)-VP16.
Luminometric measurements were normalized to Renilla luciferase internal activity and
reported as relative luminescence intensities. (B) SH-SY5Y cellswere transfectedwith siElk-1
plasmids in the indicated amounts, and RT-PCR assays were carried out for mcl-1 message.
cDNAs were normalized for GAPDH expression as shown.
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plasmid (Fig. 6C).
To provide further evidence for a role of Elk-1 in regulating the
human SMN promoter, we performed the opposite study, i.e., we
overexpressed exogenous Elk-1 in SH-SY5Y cells to see whether SMN
levels change accordingly. The results showed that the level of SMN
transcript was increased in a dose-dependent manner with increasing
levels of Elk-1–VP16 (Fig. 7A).Fig. 6. The Survival-of-motor-neuron (smn) promoter is a novel target for Elk-1 inmediating
neuronal survival. (A) SH-SY5Y cells were transfected with either scrambled RNA (scrRNA)
plasmid or siElk-1 plasmid (4 μg each), and RT-PCR assays were carried out for the SMN1
message. The same primers also amplify an alternatively-spliced isoform, SMN2 (see text for
details). cDNAs were normalized for GAPDH expression as shown. (B) SH-SY5Y cells were
transfectedwith either scrambled RNA (scrRNA) plasmid or siElk-1 plasmid (4 μg each), and
the cell lysates were analyzed for anti-SMN reactivity. Anti-actin antibody was used as a
control. (C) The activation of the SMN promoter by Elk-1. The SMN promoter containing two
etsmotifs was cloned into a luciferase reporter construct. SH-SY5Y cells were co-transfected
with the SMN-Luc reporter construct along with either pCDNA3 empty control plasmid,
expressionplasmidencodingElk-VP16, or siElk1plasmid. Luminometricmeasurementswere
normalized to Renilla luciferase internal activity and reported as relative luminescence
intensities (*pb0.03; **pb0.2).To show whether siElk-1-mediated cell death could be rescued by
SMN, and if SMN is a likely target of Elk-1 in relation to its survival
function, we co-transfected the SH-SY5Y cells with either scrRNA or
siElk-1 along with increasing amounts of SMN expression plasmid. In
either scrRNA- or siElk-1-transfected cells, co-transfection of the SMN
resulted in a decrease in caspase activity in a dose-dependent manner
(Fig. 7B), indicating loss of SMN is at least one of the reasons behind
siElk-1-induced apoptosis and that SMN can behave as a pro-survival
factor, at least to a certain extent.
We also created single or double mutations of the etsmotifs on the
SMN promoter to identify the importance of these sequences to the
transactivation of this promoter via Elk-1. Elimination of either one or
both of those motifs results in a decrease in the basal levels of SMN
promoter activation, however when the reporter constructs were co-
transfected with the Elk-VP16 expression plasmid it was observed
that the second etsmotif (ets2) has a more pronounced impact on the
activated levels of transcription from this promoter (Fig. 8A).
Therefore, we wanted to investigate binding of Elk-1 to this second
ets motif in chromatin immunoprecipitation assays (ChIP). We
transfected the cells with either wildtype (SMN-Luc) or deleted
(SMNΔ1-Luc or SMNΔ2-Luc) reporter constructs, along with the Elk-
Flag expression plasmid. Exogenous Elk-1 was immunoprecipitated,
and the subsequent PCR for the ets2 region showed that Elk-1
physically binds to this region in the wildtype reporter or the SMNΔ1-
Luc construct, but not in the SMNΔ2-Luc construct. This provides
further evidence that ets2 motif in the SMN promoter is a genuine
direct target for regulation by Elk-1 in neuroblastoma cells (Fig. 8B).
When a similar PCR was performed for the ets1 region, however, very
little, if any, binding to Elk-1 was observed either in the wildtype
reporter or the deletion mutants (around 20% in ets1 PCR as opposed
to around 80% in ets2 PCR for wildtype sequence; Fig. 8B). The SMNΔ2
deletion caused nearly total loss of binding by Elk-1 to the ets2 motif
as well as the ets1motif, whereas SMNΔ1 deletion caused very little, ifFig. 7. ElkVP16 regulates SMN transcription and SMN overexpression can rescue siElk1-
induced apoptosis. (A) SH-SY5Y neuroblastoma cells were transfected with either a control
plasmid or increasing amounts of an expression plasmid encoding ElkVP16, as indicated, and
RT-PCR was performed to analyze the levels of elk-1 and smn1 expression. (B) SH-SY5Y cells
were transfected with plasmids encoding either scrambled RNA (scrRNA) or siElk-1, in the
presenceof either a control plasmidor increasingamountsof an expressionplasmidencoding
SMN. Caspase activation as an indicator of apoptosis was quantiﬁed using CaspACE Assay
System (Promega). Statistical analyses are employed as described in Section 2.5. (*pb0.1 vs
control).
Fig. 8. Elk-1 binds to ets motifs on the SMN promoter. (A) The ets motifs on the SMN
promoter were deleted either singly (SMNΔ1- and SMNΔ2-Luc) or doubly (SMNΔ1Δ2-
Luc), and constructs were analyzed for transactivation by Elk-VP16. The SH-SY5Y cells
were co-transfected with the luciferase reporter constructs, either pCDNA3 empty
control plasmid or Elk-VP16 expression plasmid, and Renilla luciferase control plasmid.
Luminometric measurements were normalized to Renilla luciferase internal activity
and reported as relative luminescence intensities. (B) Chromatin IP assays in SH-SY5Y
cells cotransfected with Elk-Flag expression plasmid with either wildtype or deleted
smn-Luc reporter plasmids. Quantiﬁcation is done by measuring intensities of bands
(QuantityOne software, BioRad) and normalizing as discussed in Section 2, and
reported with respect to input bands. Flag-agarose beads were used to precipitate Elk-1
in the cells, and binding to ets2motif in all reporter constructs was measured (deletions
were 3-bp deletions, while the ets2-containing region ampliﬁed in the ChIP assay
spanned around 200 bp). The input shows the ampliﬁcation of DNA isolated before
immunoprecipitation. Anti-IgG antibody was used as a control antibody. The gels are
representative images of duplicate samples.
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region in this construct is probably not a primary binding site for Elk-1
(Fig. 8B). This result also explains why very little decrease is observed
in the luciferase assays when Elk-1–VP16 is expressed in the presence
of the SMNΔ1-Luc construct, but almost a complete inhibition of
activation is found when cells are transfected with Elk-1–VP16 and
the SMNΔ2-Luc constructs (Fig. 8A).
4. Discussion
ETS domain transcription factors are characterized by a winged
helix–turn–helix DNA binding domain that recognizes the consensus
core sequence GGA, known as the ets motif [4,18,19]. One of the
subfamilies within the ETS domain transcription factors is the ternary
complex factor (TCF) subfamily, which is comprised of Elk-1, Sap-1a,
Sap-1b, Fli1 and Net [1]. TCF factors bind to their respective
recognition motifs as partners with serum response factor (SRF),
which recognizes a nearby CArG box [20], the two motifs collectively
known as the serum response element (SRE). This deﬁnition of TCFfactors often resulted in their association with mitogenic response of
cells. However, TCF proteins have been correlated with various
developmental events. We and others have shown that Elk-1, for
example, is associated with neurons and the neuronal cytoskeleton
[5,7,21,22].
In order to further understand the function of Elk-1 in healthy and
injured neurons, we studied the impact of Elk-1 expression both in
cell line models and in a primary neuronal culture system. In PC12
cells, the expression of a dominant negative form of Elk-1 resulted in
apoptosis, while overexpression of wild-type Elk-1 rescued these cells
from cobalt chloride-induced cell death. Furthermore, RNAi-mediated
downregulation of Elk-1 expression resulted in increased caspase
activity in SH-SY5Y cells. In the primary DRG culture system, within
minutes after axotomy Elk-1 immunoreactivity increased signiﬁcantly
within the cell body while its phosphorylated form accumulated with
slower kinetics. When the 5′- and 3′-UTRs within the elk-1 mRNA
were bioinformatically analyzed, putative dendritic and axonal
localization motifs were found (currently under investigation),
which may explain the relatively fast accumulation of Elk-1 protein
in DRGs upon axotomy.
It should be noted that the results of our neuronal injury experiments
does not conclusively showwhether Elk-1 rescues neurons fromdeath, or
whether those neurons in the process of dying simply cease to express
high levelsof Elk-1;however combinedwith the results fromcell lines and
the novel target genes identiﬁed in this study (see below), our working
model is that Elk-1 acts as a neuroprotective agent. In this study we
provide evidence that human Elk-1 exerts its neuroprotective role
through the regulation of a pro-survival gene MCL-1 and a novel target
SMN.
Reduced levels of SMN protein are known to affect lower motor
neurons in Spinal muscular atrophies (SMA), an autosomal recessive
disorder. This disorder mainly affects the SMN1 gene, but SMN2
cannot effectively compensate for this loss. In mice, disruption of the
mouse Smn gene is embryonic lethal [23]. Exogenous SMNwas shown
to prolong PC12 cell survival under serum-deprived conditions, and to
protect NGF-differentiated PC12 cells, but it could not by itself protect
against etoposide- or UV-induced apoptosis in these cells [24]. SMN
proteins are ubiquitous proteins that function in snRNP assembly,
thus reduced levels may affect RNA splicing of genes required for
neuronal function, although this hypothesis is still under investigation
(reviewed in [25]). Injection of wildtype SMN to smn-deﬁcient
zebraﬁsh has been shown to rescue the motor axon defects; whereas
some mutations failed to rescue the motor axon defects while
retaining snRNP function. This brings to mind the question of whether
SMN has an RNA transport role in neurons, in addition to involvement
in snRNP biogenesis [26]. A pro-survival role for SMN has been
indicated for neurons, in several studies where delivery of SMN to
SMA model mice resulted in prolonged survival and restored motor
function [27–29], making SMN a particularly important target for Elk-
1 in neuronal survival response.
The promoter sequences on both telomeric and centromeric copies
(SMN1 and SMN2, respectively) are almost identical [17]. When the
promoter for SMNwas examinedwehave observed that they contain two
etsmotifs to which TCF proteins could potentially bind; a previous report
on both human and mouse SMN promoters have also indicated putative
Ets-1 binding motifs [30]. Reporter constructs with either wildtype
sequence or single or double etsmotif deletions have conﬁrmed that Elk-1
could indeed regulate this promoter, and RNAi-mediated degradation of
endogenousElk-1 reduced levels of SMN transcript (either both SMN1 and
SMN2, or an alternatively transcribed SMN1; our experiments are not
designed to distinguish between these two possibilities since it is not the
primary aim of this study), as well as protein (Fig. 6), in spite of the fact
that the levels of transcription fromthesepromoters havepreviously been
shown to be higher in primary neuronal cultures than in cell lines [17].
Furthermore, chromatin IP assays indicate that the ets2 motif present
within the SMN1promoter is bound by Elk-1 and this binding can activate
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expression of SMN can rescue siElk-mediated apoptosis in SH-SY5Y
cells. We therefore believe that SMN is a genuine novel target for
regulation by Elk-1 in protecting neuronal cells from apoptosis.
Elk-1 is involved in the regulation ofmany neurodegeneration-related
genes, or is regulated by them. It is interesting to note that overexpression
ofα-synuclein, the insoluble aggregates ofwhich is known to accumulate
in Parkinson's disease, affects Elk-1 phosphorylation through MAPK
signaling, which restores decreased cell viability [31]. Moreover α-
synuclein forms a complex with Elk-1 in cultured cell lysates, most likely
through ERK/MAPK, and Elk-1 reactivity is present in glial cytoplasmic
inclusions (GCIs) [32]. Furthermore, it was shown that the etsmotif in the
promoter sequenceofpresenilin1gene(mutationsofwhichareassociated
withAlzheimer's disease)was regulated by twoETSdomain factors: ER81
activated from the sequence, whereas Elk-1 was shown to repress it at
high doses [33]. Etsmotifs in the promoter region of the Cu/Zn superoxide
dismutase gene SOD1, the only known gene associated with the
neurodegenerative disorder amyotrophic lateral sclerosis (ALS), was
shown to be activated by Elk-1 [34]. It would be interesting to see if the
ELK-1 gene in humans carries any loss-of-function mutations in
spinomuscular atrophy (SMA) and the above-mentioned neurodegener-
ative diseases, and whether Elk-1 is, or could be used as, a general
neuroprotective regulator against these degenerative processes.
Elk-1 phosphorylationwas shown to increase in hippocampal regions
of mice upon fear conditioning [35]. Whether this phosphorylation is
related to survival of certain neurons in the circuitry is not yet known.
Phospho-Elk-1 was shown to interact with neuronal microtubules,
including those in the axon, but most phospho-Elk-1 species were
shown to translocate to the nucleus upon serum stimulation [7], while
ERK-dependent Elk-1 phosphorylation on Serines 383 and 389 was
shown to drive the nuclear translocation of Elk-1, followed by SRE-
dependent transcription in neurons [36]. Together with the data
presented in this study, we hypothesize that both of these events are
likely to enhance the survival of neurons.
However, there have been some contradictory reports, indicating a
potential role for Elk-1 in promoting apoptosis in neurons. In one study,
Elk-1was found to be associatedwithmitochondria in the adult rat brain,
and in particular themitochondrial permeability transition pore complex
(PTP). Electroporation of primary neural cultures led to a decrease in cell
viability in these experiments, and a PTP inhibitor effectively blocked cell
death, indicating that Elk-1 transfected into these cells caused apoptosis
[37]. Another study by the same group further showed that photo-
transfection of Elk-1 mRNA to neurites resulted in increased cell death,
whereas phototransfection into cell bodies does not [38]. Elk-1 in this
study is assumed to be translated in the dendrites and translocated to the
nucleus to cause cell death in a transcription-dependent manner. It was
shown previously that an alternative translation product called short
Elk-1 (sElk-1, [6]) had opposing role to long Elk-1, and that sElk-1 can
regulateneuronaldifferentiationofPC12cells [22],without anysigniﬁcant
apoptosis or cell death. Therefore it is quite possible that these results are
not contradictory, but simply that speciﬁc intracellular localization of
various isoforms of Elk-1 in combination with different upstream signals
may dictate whether the outcome for the neuron will be survival,
proliferation or cell death. In other words Elk-1 may present a critical
decision-making point for the neuron where various signals converge,
although the exact mechanism of how andwhen such a decision is made
is yet to be investigated, and is critical for a potential neuroprotective role
for Elk-1 in therapeutics.
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